Sean I. Tracy
University of Minnesota · 64 works · 10,427 citations · h-index 14
Top works
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255
- The pathogenesis of Epstein–Barr virus persistent infection
- Persistence of Epstein-Barr Virus in Self-Reactive Memory B Cells
- The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non‐follicular indolent B‐cell lymphomas
- Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL
- Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression
- Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma
- Phenotypic and Functional Diversity in Regulatory T Cells
- Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemia
- Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-Cell ALL: Outcomes and Novel Insights from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)
- Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL
- Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy
- Cytotoxic CD4 T cells in the mucosa and in cancer
- Patients with TP53-Mutated Acute Myeloid Leukemia Receiving Intensive Induction Therapy Have Superior Outcomes Due to a Higher Rate of Salvage Therapy: A Single Institution, Retrospective Study
- Impact of Prior Response to Blinatumomab on Outcomes of Brexucabtagene Autoleucel (Brexu-cel) in Adult Patients with Relapsed or Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA)
- Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL.
- In-vitro effects of pemetrexed on bronchioloalveolar and adenocarcinoma of the lung
- Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL
- Rare case of simultaneous enterococcal endocarditis and prosthetic joint infection